Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to
postacute sequelae in multiple organ systems, but evidence is mostly limited to the first year …

The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …

Long COVID—the umbrella term that encompasses the post-acute and long-term sequelae
of SARS-CoV-2 infection—can be profoundly disabling and might affect people for a lifetime …

Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …

Objective To examine whether treatment with the antiviral agent molnupiravir during the first
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …

Objective To estimate the effectiveness of nirmatrelvir, compared with no treatment, in
reducing admission to hospital or death at 30 days in people infected with the SARS-CoV-2 …

To date, there is a lack of randomized trial data examining the use of the antiviral
nirmatrelvir/ritonavir in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Objectives Real-world data on continued effectiveness of nirmatrelvir/ritonavir against
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …

In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were
introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this …

Aims Long COVID syndrome has had a major impact on million patients' lives worldwide.
The cardiovascular system is an important aspect of this multifaceted disease that may …